Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2
diabetes (T2D). Several pivotal phase III trials have been completed with evidence of …

ABSTRACT Interleukin-6 (IL-6) is a proinflammatory cytokine that decisively induces the
development of insulin resistance and pathogenesis of type 2 diabetes mellitus (T2DM) …

Beta cell dysfunction and insulin resistance are inherently complex with their interrelation for
triggering the pathogenesis of diabetes also somewhat undefined. Both pathogenic states …

Pancreatic β-cell dysfunction plays an important role in the pathogenesis of both type 1 and
type 2 diabetes. Insulin, which is produced in β-cells, is a critical regulator of metabolism …

Diabetes mellitus is increasing at an alarming rate and has become a global challenge.
Insulin resistance in target tissues and a relative deficiency of insulin secretion from …

For many years, adipose tissue was considered as an inert energy storage organ that
accumulates and stores triacylglycerols during energy excess and releases fatty acids in …

The pathology of type 2 diabetes is complex, with multiple stages culminating in a functional
β‐cell mass that is insufficient to meet the body's needs. Although the broad outlines of the …

There is an epidemic of diabetes in Asia. Type 2 diabetes develops in East Asian patients at
a lower mean body mass index (BMI) compared with those of European descent. At any …

Type 2 diabetes is a common metabolic disorder related to insulin resistance, or deficiency
of insulin secretion, caused by decreased insulin sensitivity and destruction of islet structure …

Type 2 diabetes mellitus (T2DM) is one of the major causes of premature morbidity and
mortality worldwide with the World Health Organization reporting that 1 in 10 adults …